Table 2.
Efficacy of TCZ-SC and TCZ-IV in patients with active RA
| Study | Mean duration of RA (years) | Previous failed TNF-i therapy | # of patients | Study duration (weeks) | TCZ treatment | Combined DMARDs | ACR 20 (%) | ACR 50 (%) | ACR 70 (%) | DAS remission rate (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| MATSURI34 | 7.8 | 18.75% | 32 | 25 | SC 81 mg q2w* | No (mono) | 38 | 38 | 38 | 50 |
| SC 162 mg q2w | 83 | 83 | 50 | 83 | ||||||
| SC 162 mg qw | 92 | 92 | 67 | 100 | ||||||
| BREVACTA37 | NA | 21% | 437 | 24 | SC 162 mg q2w | Yes | 61 | 40 | 20 | NA |
| Placebo | NA | NA | NA | NA | ||||||
| MUSASHI36 | 7.6 | 21.2% | 348 | 24 | SC 162 mg q2w | No (mono) | 79.2 | 63.5 | 37.1 | 49.7 |
| IV 8 mg/kg q4w | 88.5 | 67.3 | 41.0 | 62.2 | ||||||
| SUMMACTA35 | 8.7 | 21% | 1,262 | 24 | SC 162 mg qw | Yes | 69 | 47 | 24 | 38 |
| IV 8 mg/kg q4w | 73 | 49 | 28 | 36 |
Notes: Data are from a report by the MATSURI study,34 the BREVACTA study,37 the MUSASHI study,36 and the SUMMACTA study.35
*
Dosing frequency was increased to qw at week 9 in the 81 mg q2w group.
Abbreviations: RA, rheumatoid arthritis; TCZ, tocilizumab; SC, subcutaneous; IV, intravenous; TNF, tumor necrosis factor; TNF-i, TNF inhibitor; DMARDs, disease-modifying antirheumatic drugs; ACR, American College of Rheumatology; DAS, disease activity score; DAS remission, DAS <2.6; mono, TCZ monotherapy; q2w, every 2 weeks; qw, every week; q4w, every 4 weeks; NA, not available.